Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TroFuse-011: Sac-TMT (MK-2870) ± pembrolizumab vs physician's choice in first-line PD-L1-low unresectable/metastatic TNBC
CTR20251453Phase 3Active
- Sponsor
- MSD
- Start
- Apr 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sacituzumab govitecan in breast cancer, sponsored by MSD. Started Apr 2025; status: active.
02
Drugs
sacituzumab govitecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20251453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251453.